Quotient Sciences Advances AI-Designed Drug Product into Clinical Development
Phase I study of an AI-designed oral formulation sets a new standard in drug development NOTTINGHAM, England, May 28, 2026 /PRNewswire/ -- Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial...
Phase I study of an AI-designed oral formulation sets a new standard in drug development NOTTINGHAM, England, May 28, 2026 /PRNewswire/ -- Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.